Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges.

J Oncol · 2022 · PMC9668468 · PMID 36405248

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

only marginally significantP =0.055so close (0.05 < p ≤ 0.1)

Combination with other thrombopoietic agents including thrombopoietin or recombinant human interleukin-11 (rhiL-11) significantly enhanced the outcome of avatrombopag treatment ( P =0.006), while splenectasis hindered the increase in platelet count, although the difference was only marginally significant ( P =0.055).

also in 5,085 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.